Compare Ishares Msci Brazil ETF (EWZ) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Zimmer Biomet Holdings Inc — how do they compare? Ishares Msci Brazil ETF trades at $43.54 (market cap $11.30B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Ishares Msci Brazil ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| EWZ | ZBH | |
|---|---|---|
Market Cap | $11.30B | $16.95B |
Volume | 44,036,597 | 2,505,240 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.54 | $103.98 |
52-Week Low | $28.79 | $79.58 |
Typical Hold Time | 50 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, trades at $42.59, up 0.52% today, with a bullish technical signal from moving averages but overbought RSI readings. The ETF is heavily influenced by Brazil's upcoming October 2026 election, with institutional investors accumulating call options betting on a favorable outcome. Recent news highlights EWZ as a diversifier from U.S. tech exposure, though it faces competition from lower-fee alternatives like FLBR.
The outlook for EWZ hinges on Brazil's election result and commodity trends, offering asymmetric upside if pro-market policies prevail. Key risks include political volatility, U.S. tariff impacts, and currency fluctuations. Wall Street sentiment is cautiously optimistic, with unusual options activity signaling speculative interest in near-term gains.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and maintains a solid gross profit margin of 69.87%. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated. Analyst consensus is a 'Buy' with a $103.11 price target, indicating potential upside from current levels.
The outlook for ZBH is cautiously optimistic, supported by earnings momentum and a diversified medical technology portfolio. Key risks include rising debt levels, with debt-to-asset ratio increasing to 32.57% in 2025, and competitive pressures in the healthcare sector. Institutional ownership trends show continued interest, but investors should monitor margin sustainability and capital expenditure efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
